FDA Brief

Warning letters Drugs

FDA warning letter to

Fresh Farms LLC

High riskIssued Apr 19, 2022Posted Apr 26, 2022Division of Pharmaceutical Quality Operations IV

FDA warned Fresh Farms LLC about manufacturing violations in OTC hand sanitizer, including untested ethanol and missing batch records.

What happened

FDA inspected Fresh Farms LLC's drug manufacturing facility in Las Vegas, NV, from November 8 to November 11, 2021. FDA found the company lacked an adequate quality unit, did not test incoming components such as ethanol for methanol before use, did not perform release testing, and had no executed batch records for its OTC hand sanitizer. The company said it stopped drug production at the facility.

What FDA found

  1. The company did not have an adequate quality unit, and its quality-control responsibilities were not written down or fully followed.

    21 CFR 211.22(a) and 211.22(d)
  2. The company did not sample, test, or examine incoming components, including ethanol, before use, and did not test ethanol for methanol.

    21 CFR 211.84(a)
  3. The company did not test each batch for identity and strength before release.

    21 CFR 211.165(a)
  4. The company did not prepare executed batch production and control records.

    21 CFR 211.188

What FDA wants

FDA tells Fresh Farms LLC to respond in writing within 15 working days with what it has done to correct the violations and prevent recurrence, and to give a completion schedule if it cannot finish in that time. FDA also says the firm must notify FDA before resuming drug manufacturing.

Who should pay attention

  • brands that buy OTC hand sanitizer from contract manufacturers
  • contract manufacturers of alcohol-based hand sanitizer
  • companies that rely on product owners to source ethanol or other drug components

This is a summary. Read the original letter on fda.gov.

Similar letters to other companies

  1. Natural Essentials, Inc.

    FDA warns Natural Essentials over OTC drug manufacturing violations, including inadequate failing test result investigations and missing component identity tests.

    High risk
  2. Shenzhen Benliju Biotech Co., Ltd.

    FDA: Shenzhen Benliju Biotech released OTC drugs labeled sterile without sterility testing or process validation.

    High risk
  3. LGM Pharma Solutions, LLC

    FDA warned LGM Pharma Solutions over manufacturing-quality failures in failing-result investigations and process validation for tablets, including a recalled product.

    High risk
  4. Penn Herb Company, Ltd.

    FDA warned Penn Herb Company over CGMP violations and an undeclared tree-nut allergen in three dietary supplements.

    High risk